Original Article intROductiOn Cirrhotic cardiomyopathy (CCM) describes a state of impaired cardiac reserve function in patients with liver cirrhosis characterized by a systolic incompetence to stress, diastolic dysfunction, and electrophysiological abnormalities.
Diagnostic criteria for cirrhotic cardiomyopathy
We used the following criteria for the diagnosis of CCM [2] 1. Diagnostic a. Systolic dysfunction:
• Resting ejection fraction <55% • Blunted increase, i.e., <10% increase in left ventricular ejection fraction (LVEF) after exercise, volume challenge, or pharmacological stimuli. b. Diastolic dysfunction:
• The ratio of early to late (atrial) phases of ventricular filling (E/A) ratio <1.0 (age corrected).
Supportive
• Prolonged corrected QT (QTc) interval,
• Enlarged left atrium.
Methodology
Baseline patient information included age, gender, nationality, weight, height, body mass index, details of alcohol, smoking, and use of tobacco. Clinical details included duration of cirrhosis, comorbidity, and cirrhosis-related complications (variceal bleed, ascites, spontaneous bacterial peritonitis, acute kidney injury, and hepatic encephalopathy).
Baseline laboratory parameters noted were hemogram, liver biochemistry, serum creatinine, screening for hepatitis B and C virus, Wilson's disease, hemochromatosis, and autoimmune liver disease. All patients had triple-phase computed enhanced tomography. Severity of liver disease was assessed by Child-Turcotte-Pugh (CTP score) and model for end-stage liver disease (MELD) score.
Cardiac evaluation
Medications such as β-blockers were discontinued for 48 h before cardiac evaluation. Assessment of cardiac status was measured by resting pulse rate, systolic-diastolic blood pressure, and an electrocardiography (ECG) with standard 12-lead ECG (GE MAC 1200). QT interval was measured in lead II limb.
Assessment of left ventricular systolic dysfunction

Transthoracic echocardiographic examination (two-dimensional echo; Model: General Electric Vivid E9)
Resting LVEF was calculated using Simpson's rule in apical four-chamber view. A value of <55% indicated left ventricular systolic dysfunction.
Dobutamine stress test
This test was done to unmask trivial CCM by administering dobutamine, a β1-receptor agonist. The drug was injected at an initial rate of 5 μg/kg/min and then gradually increased at 3-min interval to 10, 20, 30, and 40 μg/kg/min, to achieve, at least, 85% of maximum target heart rate predicted for that particular age. In case maximum heart rate was not achieved, atropine (0.25 mg given each minute to a maximum dose of 1 mg) was added to the 40 μg/kg/min dobutamine infusion. After the test, intravenous metoprolol (2.5 mg) was given every 5 min to a maximum dose of 10 mg until the basal heart rate was achieved. Reduced left ventricular contractile reserve was defined when the increase in LVEF was less than 10% of the basal value.
Assessment of left ventricular diastolic dysfunction Pulse Doppler flowmetry
This assessed the pulse Doppler flow across the mitral valve. The denominators noted were peak early filling (E-wave) velocity and late diastolic atrial filling (A-wave) velocity. An E/A ratio was calculated [ Table 1 ].
Tissue Doppler imaging
This provided an average early diastolic myocardial velocity, i.e., e' at septal and lateral aspects of the mitral annulus and graded as mild (Grade I), moderate (Grade II), and severe (Grade III) left ventricular diastolic dysfunction [LVDD] [ Table 1 ].
[3]
Supportive measures
A left atrial size > 38 mm (is it the dimension of the left atrium or the wall thickness) was taken as a dilated. This was measured in apical four-chamber view.
QTc interval, i. e., QTc interval was calculated using Bazett's formula (QTc = QTmax in ms/[RR interval in ms] 1/2 interval). An interval of >440 ms was considered as prolonged.
Coronary angiogram
This was considered as mandatory in patients above 60 years and those with known coronary artery disease and/or type 2 diabetes mellitus for 10 years and more.
For our study, a diagnosis of CCM was considered when a cirrhotic patient had definite criteria of either systolic or diastolic dysfunction with or without supportive criteria of QTc prolongation and dilated left atrium. Patients consuming significant alcohol or diabetics of long-standing duration were not excluded from the study. This was done to determine the effects of other associated causes of CCM. However, those with CAD were excluded from the analysis as these were likely to cause an ischemic cardiomyopathy.
Intraoperative data
Intraoperative data included need for two or more inotropic support, dysrhythmia, and pulmonary edema.
Postliver transplantation
Patients were under strict cardiac surveillance in the posttransplant intensive care unit. Cardiac monitoring was ≥2 >15 E/A ratio: Early diastolic/atrial filling ratio, LVDD: Left ventricular diastolic dysfunction, E/e': The ratio between mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (e') Impact of cirrhotic cardiomyopathy on posttransplant survival There were 6 (14.7%) deaths during follow-up at 3 months and 7 (7.3%) among the 96 patients without CCM. Statistically, there was no difference in the survival between the two groups (P = 0.234) [ Figure 2 ]. However, nonsurvivors in Post LT CCM had a significantly higher MELD score (24 vs. 20, P 0.00014) and LVDD (100% vs. 11.2%, P = 0.00001) compared to survivors. None of the other demographic, etiological, and comorbid diseases and cardiac parameters affected survival [ Table 4 ].
discussiOn
One-third of our patients with liver cirrhosis had CCM. The short-term mortality following LT was 14.7%, with no done by means of ECG and two-dimensional echo, and cardiac dysfunction was graded as improved, deteriorated, no change, or normalization at 1 and 3 months.
Statistical analysis
All parameters were expressed as absolute numbers and percentages. Age, CTP, and MELD scores were expressed as median and range. Comparison of two medians was by Mann-Whitney U-test and for proportions by Chi-square test through contingency tables. Survival was assessed with Kaplan-Meier survival plot. P < 0.05 was considered statistically significant.
Results
Five hundred and eighty-six patients with liver cirrhosis underwent cardiac evaluation. One hundred and ninety-eight (33.78%) patients had CCM, 41 (20.7%) of whom had a LT and were followed up for 3 months. The remaining were either lost to follow-up (62) or expired (56) within a month or were patients who had a LTx at a satellite center within the state of Tamil Nadu (39) and followed up thereafter in the same center; perioperative data were not accessible for these 39 patients.
Baseline characteristics (41 patients)
Majority of the participants were men (73.2%) with a median age of 47 years; more than three-fourth had LDLT and had a high MELD score. Two patients had systolic and 10 had diastolic dysfunction. About 87.8% had prolonged QTC interval. None of the patients had a positive dobutamine stress test [ Table 2 ].
In the intraoperative period, of the 41 patients, 33 patients (80.5%) had hypotension and required inotropes, 11 patients (26.8%) had pulmonary edema, and 4 (1%) had dysrhythmia (tachyarrhythmia in 3 and bradyarrhythmia in 1). Table 3 and Figure 1 ], at the end of 3 months, approximately a third of patients (12; 29.3%) showed an improvement in diastolic function with no change in 21 (51.2%) and deterioration in 8 (19.5%). QTc showed no significant improvement in 35 (85.4%) patients. No discernible changes were seen either in the size of the left atrium (39 patients; 95.1%) or in the systolic function (38 patients; 92.7%). However, nonsurvivors had a higher baseline MELD score and higher prevalence of LVDD before surgery compared to survivors. Although a significant number of patients did not show any reversal of changes in cardiac parameters at 3-month follow-up, diastolic dysfunction improvement was seen in nearly a third.
Posttransplant [
The prevalence of CCM in our cohort was similar to that reported in the literature. [4] [5] [6] Post-LT, reversion of CCM was not impressive. In our series, we found that there was a significant improvement in diastolic dysfunction at the end of 3 months.
Physiologically, following a LT, there is a significant increase in blood pressure and peripheral vascular resistance with restoration of normal liver function and portal pressure. However, in patients with CCM, in the 1 st week following a LT, there is further deterioration in cardiac function secondary to hypertensive side effects of the calcineurin inhibitors causing an increase in cardiac after load. With restoration of portal flow, there is a volume overload to the heart resulting in further decompensation. [7] LV diastolic function continues to worsen until hemodynamic stability is established which may take place until 6 to 12 months post-LT during which there is recovery of functional, structural, and electrophysiological abnormalities, normalization of the systolic response to stress, improvement in diastolic dysfunction, and regression of ventricular wall thickness. [8] Improvement of QT prolongation occurs in approximately 50% of patients. [9] [10] [11] Large observational differences on the outcome of LT on CCM have been reported in different series. These may be related to differences in ethnicity, nutritional status, etiology of cirrhosis, and severity of disease. Ibrahim et al., [12] in a 4-year follow-up study from Cleveland Clinic, reported that post-LT, there was a significant increase in LV mass index and a high prevalence of diastolic dysfunction with a significant reduction in QTc. Torregrosa et al. [13] reported a significant improvement in cardiac measurements at 6 and 12 months in 15 patients who underwent LT for CCM.
In our study, we found that among patients with CCM and those without CCM, higher baseline MELD score and LVDD were associated with higher mortality. Deaths were mainly due to either sepsis [5] or surgery-related complications. [1] In CCM, LVDD is the most cardiac dysfunction and usually precedes systolic dysfunction. The presence of LVDD does not correlate with the etiology of liver disease and factual information similar to ours. [14] With increasing MELD score, the severity of LVDD worsens. [14, 15] Our observations were similar to that reported by Josefsson et al., i.e., high MELD and LVDD before transplantation correlated with an increased mortality. [16] 
Strength of the study
It includes large sample size; prospective design; exclusion of patients with coronary artery disease; use of dobutamine stress test and coronary angiography; influence of comorbid conditions such as hypertension, hypothyroid, and diabetes and alcohol; and assessment of post-LT outcome.
Limitations of the study
It includes inadequate intraoperative details; short posttransplantation follow-up; and no biomarkers such as brain natriuretic peptide which were used to confirm CCM or prognosticate these patients.
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